Be Careful NOT to Underestimate the Following Biotech Stocks (Part 2)

Theravance Biopharma: Near-Term Game-Changing PDUFAS
Some of the Prohost Portfolio selected companies are having near term PDUFAS which we believe will have a positive outcome. Indeed we expect the FDA approvals to tremendously boost these firms’ values. In Part 1 we chose Halozyme (HALO) and PTC Therapeutics (This content is for paid subscribers.

Please click here to subscribe or here to log in.